As per the contract, SAIC will provide product development services either directly or through management of subcontractors in areas including assay development, cGMP manufacture, feasibility assessments, process development, and regulatory activities.
SAIC senior vice president and business unit general manager Steve Comber said the company is pleased to assist and support NIAID with the development of biopharmaceutical products that will help prevent harmful diseases and improve human health.
The total funding could be up to $102m over the ten year period of performance, subject to availability of annual appropriations.